Table 3.
Prognostic and predictive role of MSI-H phenotype in gastric cancer.
| Author | Histology | Stage | Number of MSI-H Patients | MSI-H Frequency | Prognostic Role of MSI-H Phenotype | Prognostic/Predictive Value | Reference |
|---|---|---|---|---|---|---|---|
| Kim H et al. | adenocarcinoma | all stages | 161 | 9% | better | improved prognosis | [61] |
| An JY et al. | adenocarcinoma | all stages | 170 | 8.5% | no impact | no benefit from adjuvant chemotherapy in MSI-H patients | [62] |
| Fang WL et al. | adenocarcinoma | I–III | 25 | 11.7% | better | improved 5-year OS (68% vs. 47.6%, p = 0.030), trend towards better DFS at 3 years | [63] |
| Beghelli S et al. | adenocarcinoma | all stages | 83 | 16% | better | improved survival in stage II patients | [64] |
| Kim SY et al. | adenocarcinoma | II–III | 105 | 8.2% | better | improved prognosis without chemotherapy | [65] |
| Smyth EC et al. | adenocarcinoma | localized | 20 | 8.5% | better | worse prognosis when treated with chemotherapy | [59] |
| Polom K et al. | adenocarcinoma | metastatic | 14 | 8.0% | better | improved OS (15.9 vs. 8 months, p = 0.023) | [56] |
| Giampieri R et al. | adenocarcinoma | metastatic | 15 | 14% | better | improved overall survival | [66] |
| Corso G et al. | adenocarcinoma | all stages | 63 | 25.2% | better | improved long term survival | [57] |
| Oki E et al. | adenocarcinoma | all stages | 22 | 9.4% | No prognostic role | No prognostic role | [67] |
| Falchetti M et al. | adenocarcinoma | localized | 27 | 17% | better | improved survival (p = 0.1) | [68] |
| Marrelli D et al. | adenocarcinoma | all stages | 111 | 23.5% | better | improved 5-year survival (67.6% vs. 35%, p < 0.001) | [69] |